TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ).
Shanghai MicroPort MedBot (Group) Co., Ltd. announced a significant projected revenue increase of 70% to 80% for the first half of 2025, driven by strong sales of its surgical robots, particularly the Toumai Laparoscopic Surgical Robot. The company’s strategic focus on globalization and market expansion has also contributed to a more than 40% reduction in net loss, highlighting improved operational efficiency and cost management.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology industry, focusing on the development and commercialization of surgical robots. Its primary products include the Toumai Laparoscopic Surgical Robot, SkyWalker Orthopedic Surgical Robot, and R-ONE Vascular Interventional Surgical Robot, with a market focus on both domestic and international expansion.
Average Trading Volume: 8,555,121
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.67B
For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.